Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 14/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822680 | 0.92 | ALPL (0.64) | ALPLLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3826493 | 0.86 | HPGD (0.53) | ALPLLMNASMN1; SMN2CYP19A1ALDH1A1 | |
| SCHEMBL3827206 | 0.85 | ALPL (0.76) | ALPLLMNASMN1; SMN2 | |
| SCHEMBL3798202 | 0.84 | PPARG (0.57) | ALPL | |
| SCHEMBL3827235 | 0.84 | SLC22A12 (0.46) | ALPLLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3827260 | 0.83 | CA12 (0.52) | ALPLLMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3825143 | 0.83 | PPARG (0.47) | ALPLLMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL3827574 | 0.82 | PPARG (0.49) | ALPLLMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL3826040 | 0.82 | ALPL (0.54) | ALPL | |
| SCHEMBL14689434 | 0.81 | LMNA (0.53) | ALPLLMNASMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | claimed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | claimed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | claimed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | disclosed |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | US | disclosed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | disclosed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, GOT2 | ALPL 893/4885LMNA 2659/4885SMN1; SMN2 2500/4885 |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PYGL | ALPL 751/4885LMNA 2546/4885SMN1; SMN2 2604/4885 |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PDXK | ALPL 1637/4885LMNA 3596/4885SMN1; SMN2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.